Table 3.
Changes in efficacy variables from baseline to 24 months for those remaining on the chosen treatment (n = 726)
| Met/Incr | Met/SU | p-value* vs. Met/Incr | Insulin ± any OAD | p-value* vs. Met/Incr | |
|---|---|---|---|---|---|
| (n = 421) | (n = 154) | (n = 151) | |||
| HbA1c (%) | |||||
| BL mean ± SD | 7.4 ± 1.1 | 7.5 ± 1.4 | 8.6 ± 1.7 | ||
| Mean change vs. BL ± SD | −0.5 ± 1.0 | −0.6 ± 1.4 | 0.039 | −0.9 ± 2.0 | 0.003 |
| FPG (mg/dl) | |||||
| BL mean ± SD | 142 ± 41 | 143 ± 43 | 173 ± 66 | ||
| Mean change vs. BL ± SD | −19 ± 42 | −15 ± 41 | 0.34 | −24 ± 70 | 0.001 |
| PPG (mg/dl) | |||||
| BL mean ± SD | 201 ± 243 | 189 ± 52 | 224 ± 130 | ||
| Mean change vs. BL ± SD | 27 ± 463 | 60 ± 330 | 0.61 | 90 ± 535 | 0.066 |
| Body weight (kg) | |||||
| BL mean ± SD | 91.2 ± 17.9 | 88.1 ± 14.8 | 93.7 ± 19.6 | ||
| Mean change vs. BL ± SD | −1.5 ± 5.0 | −0.4 ± 4.8 | 0.17 | 0.8 ± 9.0 | 0.028 |
Legend: BL, baseline; Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma glucose; PPG, postprandial plasma glucose; SD, standard deviation. *Adjusted for differences in baseline characteristics: age, sex, body weight, diabetes duration, heart failure, coronary artery disease, HbA1c, FPG, and PPG.